Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone. 26028035

2016

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Using GEM models, we tested whether PI3'-lipid signaling was limiting for the promotion of KRAS(G12D)-driven lung tumors by inducing the expression of KRAS(G12D) in the absence and presence of the activating PIK3CA(H1047R) mutation. 26567140

2015

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo. 24213573

2014

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids. 25077772

2014

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors. 23959381

2013

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo. 21994468

2011

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Moreover, Klf5 is not required for lung tumor formation in an inducible oncogenic K-Ras(G12D) mouse model of lung tumorigenesis, and non-small cell lung cancer patients expressing high levels of KLF5 (21/258) have a significantly better disease-specific survival than those with intermediate to no KLF5 expression. 20639455

2010

dbSNP: rs121913529
rs121913529
0.080 GeneticVariation BEFREE Importantly, the combined inactivation of both MYC and K-ras(G12D) resulted more frequently in complete lung tumor regression. 18461184

2008

dbSNP: rs1057519847
rs1057519847
0.060 GeneticVariation BEFREE The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. 31689114

2019

dbSNP: rs1057519848
rs1057519848
0.060 GeneticVariation BEFREE The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. 31689114

2019

dbSNP: rs121434568
rs121434568
0.060 GeneticVariation BEFREE The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. 31689114

2019

dbSNP: rs121434569
rs121434569
0.060 GeneticVariation BEFREE Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging. 31132309

2019

dbSNP: rs1057519847
rs1057519847
0.060 GeneticVariation BEFREE Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors. 25596284

2015

dbSNP: rs1057519848
rs1057519848
0.060 GeneticVariation BEFREE Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors. 25596284

2015

dbSNP: rs121434568
rs121434568
0.060 GeneticVariation BEFREE Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors. 25596284

2015

dbSNP: rs121434569
rs121434569
0.060 GeneticVariation BEFREE In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent. 26058074

2015

dbSNP: rs1057519847
rs1057519847
0.060 GeneticVariation BEFREE Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties. 25320360

2014

dbSNP: rs1057519847
rs1057519847
0.060 GeneticVariation BEFREE Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice. 25164010

2014

dbSNP: rs1057519848
rs1057519848
0.060 GeneticVariation BEFREE Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice. 25164010

2014

dbSNP: rs1057519848
rs1057519848
0.060 GeneticVariation BEFREE Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties. 25320360

2014

dbSNP: rs121434568
rs121434568
0.060 GeneticVariation BEFREE Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties. 25320360

2014

dbSNP: rs121434568
rs121434568
0.060 GeneticVariation BEFREE Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice. 25164010

2014

dbSNP: rs121434569
rs121434569
0.060 GeneticVariation BEFREE Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 24931608

2014

dbSNP: rs121434569
rs121434569
0.060 GeneticVariation BEFREE Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice. 25164010

2014

dbSNP: rs1057519847
rs1057519847
0.060 GeneticVariation BEFREE Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant. 23532334

2013